Solvay Pharmaceuticals

Latest Headlines

Latest Headlines

Abbott split creates an $18B biopharma deal-maker with deep pockets

Abbott Labs's decision to separate into two distinct companies will create a research-based pharma and biologics operation with $18 billion in revenue, a lineup of marketed drugs led by Humira and a

Abbott CEO White still interested in fresh acquisitions

Abbott Labs spent more than $10 billion on new acquisitions last year, but the company's CEO says his appetite for buyouts has yet to be completely sated. "We're obviously focused on the integration

Abbott to buy Solvay pharma unit in $6.6B deal

Abbott Laboratories (ABT) is continuing on its buying spree, muscling Nycomed aside and announcing a deal this morning to buy Solvay's (SVYSY) pharmaceuticals unit for about $6.6 billion. The deal

Bidding heats up for Solvay's drug unit

Remember that potential bidding war for Solvay Pharmaceuticals? It just became more likely. Sources tell Bloomberg that Nycomed is considering a higher offer for the drugs unit of Belgium's Solvay

Sources: Abbott sparks Solvay bidding war, UCB may follow

The bidding for Solvay's pharma unit is heating up. Sources tell the Wall Street Journal that Abbott Laboratories has countered Nycomed's offer for the company. And UCB may be preparing to step in

Report: Nycomed makes potential $6.6B bid for Solvay unit

Reuters is reporting that Switzerland's Nycomed has made a €4 to 4.5 billion ($5.88 to $6.62 billion) bid for Solvay's drug unit, which has been on the market since May. Nycomed would draw on

Lundbeck, Solvay drop late-stage schizophrenia drug

Shares of Lundbeck slid after the Danish pharmaceutical group and Solvay announced that they were sounding the death knell on a late-stage drug program for schizophrenia. Researchers for the

Nycomed, others eye Solvay drug unit

Citing a "person familiar with the matter," Reuters reports that Nycomed and an unnamed Japanese company are interested in purchasing Solvay's entire drug unit, which the company put up for sale in

Solvay shelves obesity drug

Solvay took a hard look at its experimental obesity drug and decided that the regulatory hurdles it faces are simply too high. The data for SLV319--in Phase II--"confirmed its clinical activity and

Solvay ups bid for Innogenetics

It looks like Solvay, not Gen-Probe, will be buying Belgium's Innogenetics. Back in April Solvay made a